Health:Further 78 - Market Meltdown | What You Need to Know About the Latest Volatility
In this episode, Marcus covers a range of crucial topics, starting with the recent global stock market slide and its impact on the Dow, S&P 500, and Nasdaq, followed by a discussion on whether the Fed can still achieve a soft landing as rate cuts approach. He also highlights the market's rebound driven by jobless claims and discusses significant life sciences investments by venBio and TPG. Marcus then turns to healthcare policy, exploring Medicare's new coverage of cutting-edge medical devices, Centene's exit from six Medicare Advantage markets, and CVS's decision to slash profit guidance amid rising insurance costs. Additionally, he examines Walgreens' potential sale of its VillageMD stake and the stark outlook for Charles River Labs. The episode also touches on the ongoing layoffs in biotech, Hims & Hers' compounding pharmacy acquisition, Annalise.ai's Medicare NTAP approval, and the departure of an OpenAI co-founder to rival Anthropic.
------🔎RESOURCES🔎
Links:
00:00 - Intro
1:30 - Stock Market News, Aug. 5, 2024: Dow, S&P 500, Nasdaq Slide Amid Global Selloff - WSJ
4:45 - Can Fed Officials Still Nail the Landing? As Rate Cuts Near, It's a Moment of Truth - NYT
6:14 - Stock Market News, Aug. 8, 2024: S&P 500, Nasdaq, Bond Yields Jump After Jobless - WSJ
8:28 - ClaimsVenture capital veteran venBio raises $528M for life sciences investment - Fierce
8:35 - TPG tops up funds to $580M for investments across the life sciences spectrum - Fierce
11:01 - Cutting-edge medical devices will soon be covered by Medicare - Axios
13:17 - Centene to exit 6 Medicare Advantage markets: Stephens bank - Modern Healthcare
15:05 - CVS slashes profit guidance, will cut $2 billion in expenses as insurance costs climb - CNBC
18:08 - Walgreens may sell entire VillageMD stake - Modern Healthcare
22:09 - Charles River Labs Plummets 14% On 'Bleaker' Expectations For 2024 - IBD
25:53 - Fierce Biotech Layoff Tracker 2024 - Fierce
28:09 - Hims & Hers CEO defends compounding pharmacy acquisition - AXIOS